Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean aromatase inhibitor?
Displaying drugs 76 - 100 of 2437 in total

Olutasidenib

Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. IDH1 mutations are common in...
Approved
Investigational
Matched Description: … [A254726,L44256] Other IDH1 inhibitors, such as [ivosidenib], have also been approved for the treatment …
Matched Categories: … BCRP/ABCG2 Inhibitors ... MATE inhibitors ... OCT2 Inhibitors ... Enzyme Inhibitors ... MATE 1 Inhibitors …

Anacaulase

Anacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (Ananas comosus [L.] Merr.). It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides and the N-linked...
Approved
Investigational
Matched Description: … mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors …
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …

Rucaparib

Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... MATE inhibitors ... OCT1 inhibitors ... Enzyme Inhibitors ... MATE 1 Inhibitors …

Tedizolid

Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …

Capivasertib

Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. Therefore, significant research...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... BCRP/ABCG2 Inhibitors …

Cilastatin

Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, imipenem, is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Dipeptidase Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …

Brincidofovir

Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir[L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.[A235725,A235735] Due to its...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors …

Aprotinin

Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal...
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Trypsin Inhibitors ... Protease Inhibitors ... Proteinase Inhibitors ... Cholinesterase Inhibitors …

Abiraterone

Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic...
Approved
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Steroid Synthesis Inhibitors …

Fish oil

Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. More commonly, fish oil refers to the omega-3-fatty...
Approved
Nutraceutical

Elexacaftor

Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Categories: … OATP1B3 inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors …

Eltrombopag

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... UGT1A1 Inhibitors ... UGT1A3 Inhibitors ... UGT1A4 Inhibitors ... UGT1A6 Inhibitors …

Belumosudil

Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC50 100 nM vs. 3 μM, respectively). In...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... UGT1A1 Inhibitors ... UGT1A9 Inhibitors ... P-glycoprotein inhibitors …

Aprocitentan

Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker,...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... UGT1A1 Inhibitors ... UGT2B7 Inhibitors ... Cytochrome P-450 CYP2C18 Inhibitors …

Opicapone

Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management...
Approved
Investigational
Matched Description: … L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors …
Matched Categories: … COMT Inhibitors ... Enzyme Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors …

Casimersen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …

Amivantamab

Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose...
Approved
Investigational
Matched Description: … A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors …

Lasmiditan

Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. sumatriptan) have seen preferential use...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... BCRP/ABCG2 Inhibitors …

Lonafarnib

Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384,...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …

Troleandomycin

A macrolide antibiotic that is similar to erythromycin.
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …

Diosmin

Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …

Ticlopidine

Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot...
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …

Delavirdine

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …

Miconazole

Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027,...
Approved
Investigational
Vet approved
Matched Categories: … Enzyme Inhibitors ... 14-alpha Demethylase Inhibitors ... P-glycoprotein inhibitors ... Steroid Synthesis Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors …

Pexidartinib

Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial...
Approved
Investigational
Matched Categories: … MATE inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... UGT1A1 Inhibitors ... OATP1B3 inhibitors …
Displaying drugs 76 - 100 of 2437 in total